<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Caplin B</submitter><funding>Barts Charity</funding><pagination>1237-1246</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8455047</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>16(8)</volume><pubmed_abstract>&lt;h4>Background and objectives&lt;/h4>Patients receiving in-center hemodialysis treatment face unique challenges during the coronavirus disease 2019 (COVID-19) pandemic, specifically the need to attend for treatment that prevents self-isolation. Dialysis unit attributes and isolation strategies that might reduce dialysis center COVID-19 infection rates have not been previously examined.&lt;h4>Design, setting, participants, &amp; measurements&lt;/h4>We explored the role of variables, including community disease burden, dialysis unit attributes (size and layout), and infection control strategies, on rates of COVID-19 among patients receiving in-center hemodialysis in London, United Kingdom, between March 2, 2020 and May 31, 2020. The two outcomes were defined as (&lt;i>1&lt;/i>) a positive test for infection or</pubmed_abstract><journal>Clinical journal of the American Society of Nephrology : CJASN</journal><pubmed_title>Risk of COVID-19 Disease, Dialysis Unit Attributes, and Infection Control Strategy among London In-Center Hemodialysis Patients.</pubmed_title><pmcid>PMC8455047</pmcid><funding_grant_id>MGD&amp;U0002</funding_grant_id><pubmed_authors>Damien A</pubmed_authors><pubmed_authors>Clark G</pubmed_authors><pubmed_authors>Debasish B</pubmed_authors><pubmed_authors>Eirini L</pubmed_authors><pubmed_authors>Sharpe CC</pubmed_authors><pubmed_authors>Claire S</pubmed_authors><pubmed_authors>Paramit C</pubmed_authors><pubmed_authors>Kumar N</pubmed_authors><pubmed_authors>Ashby D</pubmed_authors><pubmed_authors>Catriona G</pubmed_authors><pubmed_authors>Manson B</pubmed_authors><pubmed_authors>Elham A</pubmed_authors><pubmed_authors>Hugh C</pubmed_authors><pubmed_authors>Ravi R</pubmed_authors><pubmed_authors>Antonelou M</pubmed_authors><pubmed_authors>Martin F</pubmed_authors><pubmed_authors>Daniel M</pubmed_authors><pubmed_authors>Blakey SA</pubmed_authors><pubmed_authors>Suzanne F</pubmed_authors><pubmed_authors>Ben C</pubmed_authors><pubmed_authors>Asgari E</pubmed_authors><pubmed_authors>Hayes NJ</pubmed_authors><pubmed_authors>Gisele V</pubmed_authors><pubmed_authors>Cronin H</pubmed_authors><pubmed_authors>Vinay S</pubmed_authors><pubmed_authors>Nicholas C</pubmed_authors><pubmed_authors>Aegida N</pubmed_authors><pubmed_authors>Bramham K</pubmed_authors><pubmed_authors>Nathan H</pubmed_authors><pubmed_authors>Nicola K</pubmed_authors><pubmed_authors>Kevin E</pubmed_authors><pubmed_authors>Sarnowski A</pubmed_authors><pubmed_authors>Helen C</pubmed_authors><pubmed_authors>McCafferty K</pubmed_authors><pubmed_authors>Kate B</pubmed_authors><pubmed_authors>Dandisonba BA</pubmed_authors><pubmed_authors>Sahana G</pubmed_authors><pubmed_authors>Alexander S</pubmed_authors><pubmed_authors>Pan-London COVID-19 Renal Audit Group</pubmed_authors><pubmed_authors>Maria D</pubmed_authors><pubmed_authors>Andrew F</pubmed_authors><pubmed_authors>Corbett R</pubmed_authors><pubmed_authors>Cole N</pubmed_authors><pubmed_authors>Mysore P</pubmed_authors><pubmed_authors>Sarah B</pubmed_authors><pubmed_authors>Damir T</pubmed_authors><pubmed_authors>Banerjee D</pubmed_authors><pubmed_authors>Grace C</pubmed_authors><pubmed_authors>Ford ML</pubmed_authors><pubmed_authors>Roper T</pubmed_authors><pubmed_authors>Sujanita T</pubmed_authors><pubmed_authors>Braide-Azikwe DCB</pubmed_authors><pubmed_authors>Cassim S</pubmed_authors><pubmed_authors>Rosalind B</pubmed_authors><pubmed_authors>David M</pubmed_authors><pubmed_authors>Tayeba R</pubmed_authors><pubmed_authors>Noam R</pubmed_authors><pubmed_authors>Hull R</pubmed_authors><pubmed_authors>Alan S</pubmed_authors><pubmed_authors>Bethia M</pubmed_authors><pubmed_authors>Abigail D</pubmed_authors><pubmed_authors>Lioudaki E</pubmed_authors><pubmed_authors>Richard H</pubmed_authors><pubmed_authors>Caplin B</pubmed_authors><pubmed_authors>Andrea CS</pubmed_authors><pubmed_authors>Richard C</pubmed_authors><pubmed_authors>Marina L</pubmed_authors><pubmed_authors>Katherine P</pubmed_authors><pubmed_authors>Kieran M</pubmed_authors><pubmed_authors>Srinivasa V</pubmed_authors><pubmed_authors>Heidy H</pubmed_authors><pubmed_authors>Salama AD</pubmed_authors><pubmed_authors>Frankel A</pubmed_authors><pubmed_authors>Makanjuola D</pubmed_authors><pubmed_authors>Gregor Y</pubmed_authors><pubmed_authors>Alex R</pubmed_authors></additional><is_claimable>false</is_claimable><name>Risk of COVID-19 Disease, Dialysis Unit Attributes, and Infection Control Strategy among London In-Center Hemodialysis Patients.</name><description>&lt;h4>Background and objectives&lt;/h4>Patients receiving in-center hemodialysis treatment face unique challenges during the coronavirus disease 2019 (COVID-19) pandemic, specifically the need to attend for treatment that prevents self-isolation. Dialysis unit attributes and isolation strategies that might reduce dialysis center COVID-19 infection rates have not been previously examined.&lt;h4>Design, setting, participants, &amp; measurements&lt;/h4>We explored the role of variables, including community disease burden, dialysis unit attributes (size and layout), and infection control strategies, on rates of COVID-19 among patients receiving in-center hemodialysis in London, United Kingdom, between March 2, 2020 and May 31, 2020. The two outcomes were defined as (&lt;i>1&lt;/i>) a positive test for infection or</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Aug</publication><modification>2025-04-26T16:33:48.105Z</modification><creation>2024-11-07T08:11:02.482Z</creation></dates><accession>S-EPMC8455047</accession><cross_references><pubmed>34074636</pubmed><doi>10.2215/CJN.03180321</doi><doi>10.2215/cjn.03180321</doi></cross_references></HashMap>